Sabatolimab
Sabatolimab Sabatolimab: Sabatolimab (MBG453) is a novel immuno-myeloid therapy that binds to TIM-3 on immune cells, facilitating antileukemic immune activation and phagocytic killing of leukem
Myelodysplastic Syndromes (MDS)
Decitabine and Cedazuridine
INQOVI® for adult patients with MDS or CMML who are intermediate-1, intermediate-2, and high-risk IPSS groups. It is a prescribed oral tablet combination of decitabine and cedazurine approved by the FDA for adult patients with myelodysplastic syndromes (MDS) and patients with chronic myelomonocytic leukemia (CMML) including:
Seeing Cancer From All Sides: Richard M. Stone Is Giant of Cancer Care in Leukemia
Original Publication Date
Article Source
External Web Content
Driven by his mother’s advice and his father’s memory, Richard M. Stone, MD, rose to become a global leader in leukemia care and research. Growing up, Richard M. Stone, MD, thought he was going to be an attorney like his father, but his direction in life changed when he was 15…
Anand Karnad, MD
Institution
Mays Cancer Center at UT Health San Antonio MD Anderson
Physician Status
accepting new patients
Primary Disease Area of Focus
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
About
Dr. Anand Karnad received his medical degree from Madras Medical College at the University of Madras (Chennai), in India. Dr. Karnad is Chief, Division of Hematology-Oncology at the Department of Medicine, and UT Health San Antonio MD Anderson Cancer Center and has been Professor of Medicine here since 2004. He has been an active investigator for the National Cancer Institute Clinical Trials for two decades, including trials designed to prevent and treat a range of cancers. He is principal investigator for the National Clinical Trials System (NCTN) SWOG trials at the Cancer Center. He is
Science Simplified: What is a Natural History Study?
Original Publication Date
Article Source
External Web Content
Want to learn about scientific topics without needing a PhD? Check out the Science Simplified blog from TESS Research Foundation! Dr. Tanya Brown, PhD, works with researchers to make science accessible and empower rare disease community members with scientific knowledge. Dr…
Machine learning assisted real-time deformability cytometry of CD34+ cells allows to identify patients with myelodysplastic syndromes
Original Publication Date
Article Source
External Web Content
Abstract Diagnosis of myelodysplastic syndrome (MDS) mainly relies on a manual assessment of the peripheral blood and bone marrow cell morphology. The WHO guidelines suggest a visual screening of 200 to 500 cells which inevitably turns the assessor blind to rare cell populations…
Transplant for Older Patients with MDS
Topic(s)
Bone Marrow Transplant
Presenter(s)
Linda Burns, MD
Nandita Khera, MD, MPH
In this webinar Drs. Linda Burns and Nandita Khera will discuss the advances in transplantation for older patients with MDS. Stem cell transplants are not frequently offered to older patients with high-risk myelodysplastic syndromes (MDS). According to a study from the Blood and…
Nandita Khera, MD, MPH
Institution
Mayo Clinic College of Medicine and Science
Physician Status
available for consultation
Primary Disease Area of Focus
Myelodysplastic Syndromes (MDS)
Linda Burns, MD
Institution
Center for International Blood & Marrow Transplant Research (CIBMTR)
Physician Status
available for consultation
Primary Disease Area of Focus
Myelodysplastic Syndromes (MDS)
Research Identifies How Gene Mechanisms Influence Pediatric MDS
Original Publication Date
Article Source
External Web Content
Each year, approximately 1 in every 1 million infants is diagnosed with pediatric myelodysplastic syndromes (MDS), a group of rare disorders characterized by the abnormal or deficient formation of blood cells in the bone marrow. However, researchers wanted to understand the…